https://www.biopharmadive.com/news/quralis-eli-lilly-als-drug-dementia-deal/717585/
https://www.quralis.com/news/quralis-grants-lilly-exclusive-global-license-for-qrl-204-a-potentially-first-in-class-precision-therapy-that-restores-unc13a-function-in-als-and-ftd/
From what I can gather the ALS drug that Lilly has licensed has only been tested in phase1 and subsequent phases are pending. Based on that PAA has the lead with our ODD & FDA endorsement to conduct a combined phase 2/3 trials. The ODD will also preclude competition for the exclusivity period of 7 years and 7.5 years in the EU if ODD is obtained there.
Monepantel’s modus operandi through autophagy probably is better understood and probably has more applications than QRL-204
AIMO. DYOR.
https://www.biopharmadive.com/news/quralis-eli-lilly-als-drug-dem...
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $87.51M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.3¢ | 17.5¢ | $205.5K | 1.150M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 55777 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 56756 | 2 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |